There is a published answer, and it was not written with this market in mind. The European Association for the Study of Obesity set out five interdependent pillars. Right Patient. Right Care. Right Workforce. Right Data. Right Access.
It names an Integration Paradox. The therapies advanced faster than the systems needed to use them well. That is a statement about health systems, not about telehealth sellers.
Read as a checklist it is still useful. Most sellers here publish nothing against most of it. That silence is measured three ways. There is whether disclosure is a trait a seller has. There is how invisible compounded use is in the record [2], and in what the dose-error reports list.
A specialist society has written down what it thinks good care around these drugs requires. It is not addressed to anybody selling them online. That is part of why it is worth reading here. It describes a standard set without this market in mind, and what sellers publish can be laid against it.
The paradox they name
European health systems vary in workforce capability, multidisciplinary care, reimbursement, access and monitoring infrastructure. [1] The authors argue that therapeutic innovation has outpaced the structures needed to use it well. They call that mismatch the EASO Integration Paradox.
Their closing position is unambiguous. Worth stating before anything else. The question is no longer whether incretin-based therapies should be used. It is how to implement them responsibly, inside comprehensive obesity care pathways. This is a document in favor of the drugs.
The five pillars
Right Patient. Right Care. Right Workforce. Right Data. Right Access. The authors describe them as interdependent. That is the load-bearing word. The framework is not a menu a provider picks two from.
Alongside it they set out a research and implementation agenda: real-world evidence, harmonized monitoring, workforce development, pharmacovigilance, and equitable access.
Reading the pillars against a checkout
Right Patient asks whether the person in front of you should be on this drug at all. An intake form can do a version of that. How good a version is not something a buyer can inspect from outside.
Right Care and Right Workforce are about what surrounds the prescription — dietetic input, behavioral support, someone to call. This site has covered a remote program that supplied several of those and produced results comparable to trials. It can be done remotely. It usually is not, and almost no seller here describes what they provide.
Right Data means monitoring and follow-up that goes somewhere. Right Access is the one this market arguably improves on a national system. It makes the drug obtainable to people no insurer would cover — while leaving the other four pillars to the buyer.
What to do with a framework
Use it as five questions rather than as a verdict. Who decided I should take this, and on what basis? What comes with it besides the drug? Who do I contact when something changes? What is being measured, and by whom? And what happens when I cannot pay?
Most sellers on this roster answer none of those. That is measurable rather than rhetorical. the disclosure scorecard counts what each one says, and the census of silence counts what they leave to you. A framework written for health ministries turns out to be a decent shopping list.